AR089710A1 - Composiciones farmaceuticas estabilizadas de un inhibidor del virus de hepatitis c - Google Patents

Composiciones farmaceuticas estabilizadas de un inhibidor del virus de hepatitis c

Info

Publication number
AR089710A1
AR089710A1 ARP130100099A ARP130100099A AR089710A1 AR 089710 A1 AR089710 A1 AR 089710A1 AR P130100099 A ARP130100099 A AR P130100099A AR P130100099 A ARP130100099 A AR P130100099A AR 089710 A1 AR089710 A1 AR 089710A1
Authority
AR
Argentina
Prior art keywords
hepatitis
pharmaceutical compositions
stabilized pharmaceutical
virus inhibitor
compound
Prior art date
Application number
ARP130100099A
Other languages
English (en)
Spanish (es)
Inventor
Alan Busacca Carl
Chen Feng
Jing-Gump Edwin
B Majeska Jenness
Pennino Scott
Qiu Fenghe
Fernanda Villagra Maria
Braun Mathias
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089710(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR089710A1 publication Critical patent/AR089710A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP130100099A 2012-01-12 2013-01-11 Composiciones farmaceuticas estabilizadas de un inhibidor del virus de hepatitis c AR089710A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261586087P 2012-01-12 2012-01-12

Publications (1)

Publication Number Publication Date
AR089710A1 true AR089710A1 (es) 2014-09-10

Family

ID=47628447

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100099A AR089710A1 (es) 2012-01-12 2013-01-11 Composiciones farmaceuticas estabilizadas de un inhibidor del virus de hepatitis c

Country Status (27)

Country Link
US (2) US20140037719A1 (instruction)
EP (1) EP2802313A1 (instruction)
JP (1) JP2015503616A (instruction)
KR (1) KR20140109433A (instruction)
CN (1) CN104244926A (instruction)
AP (1) AP2014007760A0 (instruction)
AR (1) AR089710A1 (instruction)
AU (1) AU2013208024A1 (instruction)
BR (1) BR112014017058A8 (instruction)
CA (1) CA2861041A1 (instruction)
CL (1) CL2014001783A1 (instruction)
CO (1) CO7000774A2 (instruction)
EA (1) EA201400808A1 (instruction)
EC (1) ECSP14013104A (instruction)
HK (1) HK1204982A1 (instruction)
IL (1) IL233550A0 (instruction)
IN (1) IN2014DN05759A (instruction)
MA (1) MA35865B1 (instruction)
MX (1) MX2014008205A (instruction)
NZ (1) NZ626353A (instruction)
PE (1) PE20141817A1 (instruction)
PH (1) PH12014501598A1 (instruction)
SG (1) SG11201404042VA (instruction)
TN (1) TN2014000295A1 (instruction)
TW (1) TW201340969A (instruction)
UY (1) UY34569A (instruction)
WO (1) WO2013106506A1 (instruction)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
EP2970335B1 (en) 2013-03-15 2019-05-08 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis c virus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5329976A (en) * 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
UY28323A1 (es) 2003-05-21 2004-12-31 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c
EP1753775B1 (en) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
WO2006130552A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
EA018603B1 (ru) 2008-09-16 2013-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
SI2358355T1 (sl) * 2008-11-21 2014-02-28 Boehringer Ingelheim Gmbh Farmacevtski sestavek potentnega inhibitorja HCV za oralno dajanje
PL2451438T3 (pl) 2009-07-07 2014-07-31 Boehringer Ingelheim Int Kompozycja farmaceutyczna inhibitora proteazy wirusowego zapalenia wątroby typu C

Also Published As

Publication number Publication date
PH12014501598A1 (en) 2014-10-08
ECSP14013104A (es) 2015-11-30
AU2013208024A1 (en) 2014-07-10
IL233550A0 (en) 2014-08-31
EP2802313A1 (en) 2014-11-19
NZ626353A (en) 2016-02-26
KR20140109433A (ko) 2014-09-15
BR112014017058A2 (pt) 2017-06-13
US20150190458A1 (en) 2015-07-09
MA35865B1 (fr) 2014-12-01
US20140037719A1 (en) 2014-02-06
TW201340969A (zh) 2013-10-16
CO7000774A2 (es) 2014-07-21
CL2014001783A1 (es) 2014-12-12
MX2014008205A (es) 2014-08-08
CA2861041A1 (en) 2013-07-18
EA201400808A1 (ru) 2015-02-27
CN104244926A (zh) 2014-12-24
AP2014007760A0 (en) 2014-07-31
JP2015503616A (ja) 2015-02-02
HK1204982A1 (en) 2015-12-11
PE20141817A1 (es) 2014-12-17
TN2014000295A1 (en) 2015-12-21
UY34569A (es) 2013-07-31
SG11201404042VA (en) 2014-08-28
IN2014DN05759A (instruction) 2015-04-10
WO2013106506A1 (en) 2013-07-18
BR112014017058A8 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
NI201600098A (es) Composiciones farmacéuticas que comprenden azd9291
EA201590457A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
NZ703064A (en) Inhibitors of hepatitis c virus
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
IL232267A (en) Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective
GEP201706698B (en) Inhibitors of influenza viruses replication
RS53209B (en) PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
EA201291410A1 (ru) Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
RU2009138047A (ru) Стабилизация витамина в12
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
AR089710A1 (es) Composiciones farmaceuticas estabilizadas de un inhibidor del virus de hepatitis c
AR083780A1 (es) Composicion farmaceutica para tratar infecciones del hcv
RS54022B1 (en) Viral inhibitor composition for in vivo therapeutic use
AR132160A2 (es) Composición farmacéutica en solución acuosa
RS54325B1 (en) PHARMACEUTICAL COMPOUNDS CONTAINING BETA GALACTOSIDASE AND ALPHA GALACTOSIDASE AND THEIR USE FOR THE TREATMENT OF GASTROESOFAGEAL REFLUX DISEASE

Legal Events

Date Code Title Description
FB Suspension of granting procedure